生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

休市中 07-24 16:00:00

5,012.642

-36.509

-0.72%

最高5,150.312	最低4,972.545	成交量1.25亿
今开5,029.704	昨收5,049.151	日振幅3.52%
总市值0.00	流通市值0.00	总股本0.00
成交额48.46亿	换手率--	流通股本0.00
市净率5.733016	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5012.642,"timestamp":1784880483699,"preClose":5049.151,"halted":0,"volume":125446609,"delay":0,"changeRate":-0.007231,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-36.508789,"latestTime":"07-24 16:00:00","open":5029.7036,"high":5150.312,"low":4972.5454,"amount":4846003249,"amplitude":0.035207,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"pbRate":5.733016,"peRate":-326.015208,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161/wiki","defaultTab":"wiki","newsList":[{"id":"2654401032","title":"科济全球首款实体瘤CAR-T获批之后 李宗海谈创新药可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=2654401032","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654401032?lang=zh_cn&edition=full","pubTime":"2026-07-25 04:10","pubTimestamp":1784923816,"startTime":"0","endTime":"0","summary":"99万定价，全球首款实体瘤CAR-T细胞疗法在中国获批。一个月前，科济药业（2171.HK）自主研发的舒瑞基奥仑赛注射液获国家药监局批准上市，这是全球首款获批用于实体瘤治疗的CAR-T细胞治疗产品。7月15日下午1点20分，科济药业位于上海徐汇区办公地址四楼的实验室大门被缓缓推开，公司创始人、董事长李宗海博士走了进来。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607253820887995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","BK1161","06978","CAR","LNGR","BK1574","MEDX","BK4022","BK4230","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653356100","title":"【新股IPO】新济医药向港交所主板递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2653356100","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653356100?lang=zh_cn&edition=full","pubTime":"2026-07-24 23:26","pubTimestamp":1784906800,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所2026年7月24日文件，广州新济医药向港交所主板递交生物科技 上市申请，独家保荐人为国泰君安国际，此前曾于2025年12月24日递表港股。核心产品DHMP、XJN010均完成II期临床，分别为国内唯一进入II期的微针镇静贴、国内首款帕金森关期鼻喷候选药，目前收入来自CRO与MAH业务，暂无自研药销售。本次募资拟用于管线临床推进、扩充生产产能、商业化布局及补充日常营运资金。","market":"hk","thumbnail":"https://static.szfiu.com/news/20220324/YzUxYTE2NDgwOTA4NjcwODA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YzUxYTE2NDgwOTA4NjcwODA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":true,"source_url":"1986762","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK1515","HEXmain","BK4127","BK1574","159938","BK1161","KCE","FRHC","09939","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653087375","title":"药捷安康-B(02617)授出合共525.89万股H股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2653087375","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653087375?lang=zh_cn&edition=full","pubTime":"2026-07-24 21:00","pubTimestamp":1784898000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，于2026年7 月24日，公司根据H股奖励计划的条款，向67名雇员参与者授出合共281.69万份股份奖励及244.2万份购股权，涉及合共525.89万股H股奖励股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653108270","title":"海南海药：公司高度重视创新药的研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653108270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653108270?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:52","pubTimestamp":1784897563,"startTime":"0","endTime":"0","summary":"证券之星消息，海南海药(000566)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问：海药获国资大力扶持，又获国家创新药板块持续投入，理应一片大好的！海南海药回复：您好，公司高度重视创新药的研发工作，正在积极推进创新药临床试验各项工作，如有新进展公司将根据规定履行信息披露义务，感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400039699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0239","159992","000566","06978","BK0188","BK1161","BK0070","BK0060","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653821850","title":"瑞博生物-B(06938)7月24日斥资约422.37万港元回购7.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653821850","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653821850?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:40","pubTimestamp":1784896814,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年7月24日该公司斥资约422.37万港元回购7.84万股，回购价格为每股52.6至54.4港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082188","title":"瑞博生物-B(06938.HK)7月24日斥资约422.37万港元回购7.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653082188?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:40","pubTimestamp":1784896814,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653081228","title":"麦科医药-B(02335)：MT200605用于急性缺血性脑卒中(AIS)的II期临床试验完成数据库锁定","url":"https://stock-news.laohu8.com/highlight/detail?id=2653081228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653081228?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:43","pubTimestamp":1784893418,"startTime":"0","endTime":"0","summary":"智通财经APP讯，麦科医药-B 发布公告，集团自主研发的用于治疗急性缺血性脑卒中的候选药物MT200605的II期临床试验已完成数据库锁定。在中国进行的MT200605用于急性缺血性脑卒中的II期临床试验为一项多中心、随机、双盲、安慰剂对照的试验，旨在评价MT200605的疗效、安全性及药代动力学。该II期临床试验于2025年9月完成首例患者入组，于2026年3月完成全部360例患者入组，于2026年6月完成最后一例患者出组，并于近期完成数据库锁定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","AIS","MDTX","BMED","PSYK","IBBJ","IBBQ","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653089506","title":"宜明昂科-B(01541.HK)7月24日斥资18.82万港元回购5.82万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653089506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653089506?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:01","pubTimestamp":1784890906,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653089692","title":"罗氏(RHHBY)眼科创新药Susvimo获欧盟CHMP积极推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2653089692","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653089692?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:46","pubTimestamp":1784890007,"startTime":"0","endTime":"0","summary":"此外，传统月度频繁注射给患者带来巨大就医负担，Susvimo 长效方案大幅降低就诊频次，具备显著临床与商业化价值。罗氏首席医学官表示，CHMP 的积极推荐将为欧洲患者带来全新低负担治疗选择。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NTNlMDYzZTc4ZWFmNGZiMGI1NGE4MDhhNDkyYzIxNWQxMTI3MjMzNjI1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTNlMDYzZTc4ZWFmNGZiMGI1NGE4MDhhNDkyYzIxNWQxMTI3MjMzNjI1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302999","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","CHMP","BK1161","RHHBY","MEDX","CANC","BK4007","FSXEmain","BK4087","159992","FESXmain","03165","HRTS","LNGR","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653085682","title":"歌礼制药-B(01672.HK)7月24日斥资178.36万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653085682","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653085682?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:08","pubTimestamp":1784887730,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01672","01477","BK1574","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653085552","title":"维立志博-B(09887.HK)联合创始人康小强自愿延长禁售期 彰显长期发展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2653085552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653085552?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:03","pubTimestamp":1784887403,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653085913","title":"京东健康以数字化能力连接药企与患者 提升创新药服务效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2653085913","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653085913?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:54","pubTimestamp":1784886840,"startTime":"0","endTime":"0","summary":"7月17日，京东买药联合新华社发布主题视频《关于吃药和生病的疑问，我们问了药企高管》上线，视频中，来自诺和诺德、诺华、赫力昂、美纳里尼、卫材中国、欧加隆、银诺医药、信达生物等多位药企负责人围绕原研药、创新药、互联网渠道、慢病管理和AI健康服务等话题进行分享，也呈现出用户购药需求的变化：从关注“能不能买到”，进一步延伸到“是否正规、是否适合、能否获得持续健康管理”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607243820590530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1591","BK1589","BK1583","SGXZ86797644.SGD","BK1574","LU0051755006.USD","BK1515","BK1571","IBBQ","BK1247","MEDX","LU0456827905.SGD","BK1161","LNGR","06978","BK1142","BK1615","SGXZ62798434.SGD","86618","159992","06618"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653083405","title":"九典制药：湖南医药发展私募基金、光证资管等多家机构于7月23日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2653083405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653083405?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:49","pubTimestamp":1784886585,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年7月24日九典制药发布公告称湖南医药发展私募基金、光证资管、鑫巢资本、前海人寿、天风证券、东方基金于2026年7月23日调研我司。全年来看，销量预期保持增长态势。公司已将代温灸膏列为重点推广品种，前期已投入大量品牌推广资源，全力提升产品市场知名度与渗透率。摩熵医药的数据显示，2023 至 2025 年国内外用贴膏剂市场复合增速为 10.27%，整体市场增长态势稳健。九典制药主营业务：医药产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400031356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK1574","BK0239","09939","300705","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653608328","title":"7月24日君实生物现1笔大宗交易 机构净买入1960.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653608328","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653608328?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:49","pubTimestamp":1784886552,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日君实生物发生大宗交易，交易数据如下：大宗交易成交价格35.65元，相对当日收盘价折价0.64%，成交55万股，成交金额1960.75万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。近三个月该股共发生15笔大宗交易，合计成交9.7万手，折价成交15笔。截至2026年7月24日收盘，君实生物报收于35.88元，下跌3.57%，换手率1.86%，成交量14.25万手，成交额5.18亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400031330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1515","01877","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653108307","title":"昆药集团：拟减持不超244.3022万股维立志博股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2653108307","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653108307?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:48","pubTimestamp":1784886520,"startTime":"0","endTime":"0","summary":"【昆药集团：拟减持不超244.3022万股维立志博股票】7月24日，昆药集团公告称，为进一步强化主业、优化资产结构，公司拟通过集中竞价、大宗交易等方式择机减持不超过244.3022万股维立志博股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607243820568626.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607243820568626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0060","BK0188","BK0028","BK0239","600422","HK0000500386.USD","HK0000252152.HKD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653083589","title":"宝济药业-B(02659.HK)7月24日斥资199.42万港元回购11.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653083589","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653083589?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:44","pubTimestamp":1784886296,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088593","title":"万润股份：生命科学与医药业务2025年实现收入约7.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653088593?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:12","pubTimestamp":1784884351,"startTime":"0","endTime":"0","summary":"证券之星消息，万润股份(002643)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问：公司三大板块医药板块还有吗？占比多少万润股份回复：您好，公司是以研发创新驱动的平台型企业，现主要从事电子信息材料产业、环保材料产业、新能源材料产业以及生命科学与医药产业四个领域产品的研发、生产和销售。其中，公司生命科学与医药业务2025年实现收入约7.48亿元，占营业收入比重20.13%。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400029698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","159938","BK0082","BK0152","BK1161","BK0132","BK1515","002643","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653003747","title":"7月24日迈威生物跌6.21%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653003747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653003747?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:39","pubTimestamp":1784882394,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日迈威生物跌6.21%，收盘报31.09元，换手率3.64%，成交量8.37万手，成交额2.67亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653707018","title":"7月24日司太立跌6.10%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653707018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653707018?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:38","pubTimestamp":1784882303,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日司太立跌6.10%创60日新低，收盘报8.0元，换手率2.79%，成交量12.24万手，成交额1.0亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为银河基金的银河医药混合A。方伟在任的基金产品包括:银河康乐股票A，管理时间为2021年5月10日至今，期间收益率为-32.32%；银河医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","603520","BK1574","159938","BK1161","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653707427","title":"礼邦医药-B(09637.HK)：悉数行使超额配股权、稳定价格行动及稳定价格期结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2653707427","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653707427?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:33","pubTimestamp":1784882032,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","09939","BK1161","BK1574","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}